USF Health endorses the standards of the ACCME and all applicable accrediting organizations that require everyone in a position to control the content of a CME activity to disclose all financial relationships with commercial interests that are related to the content of the CME activity. CME activities must be balanced, independent of commercial bias and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when individuals in a position to control the content of CME have a relevant financial relationship with a commercial interest which, therefore, may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.
USF Health will identify, review and resolve all conflicts of interest that speakers, authors or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. USF Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and commercial interests:
David Aboulafia, MD, has no significant financial relationships to disclose.
Liron Pantanowitz, MD, has no significant financial relationships to disclose.
Daniel R. Kuritzkes, MD, has disclosed that he has received consulting fees from Gilead Sciences, GlaxoSmithKline, Merck, and ViiV and funds for research support from Gilead Sciences, GlaxoSmithKline, Janssen, Merck, and ViiV. Dr. Kuritzkes disclosed in previous editions that he had received consulting fees from Bionor, Bristol-Myers Squibb, Celera, InnaVirVax, Janssen, Oncolys, Teva, Tobira, and ViroStatics and fees for non-CME/CE services from Merck and ViiV.
Joseph J. Eron, Jr., MD, has disclosed that he has received consulting fees from Gilead Sciences, Janssen, Merck, TRIO Health, and ViiV and funds for research support from Gilead Sciences, Janssen, and ViiV. Dr. Eron disclosed in previous editions that he had received consulting fees from AbbVie, Avexa, Bristol-Myers Squibb, Chimerix, EMD Serono, Inhibitex, Kainos, Koronis, Myriad, Pfizer, Roche Molecular Systems, Tobira, Tibotec/Janssen, and Virco; had received funds for research support from AbbVie, Bristol-Myers Squibb, Merck, Panacos, TaiMed, and Tobira; had served on speaker bureaus for Bristol-Myers Squibb, Gilead Sciences, Roche, Tibotec, and Virco; and had served on data and safety monitoring boards for TaiMed and Vertex.
Edward King, MA, has nothing to disclose with regard to commercial interests.
Heather Stieglitz, PhD, has nothing to disclose with regard to commercial interests.
Jennifer M. Blanchette, PhD, has nothing to disclose with regard to commercial interests.
Jenny Schulz, PhD, has nothing to disclose with regard to commercial interests.
USF Health OCPD staff members and the peer/content reviewers for this activity have no relevant financial relationships to disclose. Disclosures are on file at the USF Health Office of Continuing Professional Development.
The following faculty and staff have previously contributed to the content of this module and disclosed the following potential conflicts of interest:
Kathleen E. Squires, MD, disclosed that she had served on advisory boards for scientific purposes for Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and ViiV; had served on advisory boards for marketing purposes for Gilead Sciences and Janssen; had served on advisory boards for Boehringer Ingelheim, GlaxoSmithKline, Koronis, Pfizer, Schering-Plough, Tibotec, and Tobira; had received funds for research support from BioCryst, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Koronis, Merck, Schering-Plough, Tibotec, and Vertex; and had received consulting fees from GlaxoSmithKline and Merck at the time she contributed to this module.
Bruce J. Dezube, MD; Kristen Rosenthal, PhD; Anna Poppa; Kevin Obholz, PhD; and Lisa Gargano, PhD, MPH, had nothing to disclose with regard to commercial interests at the time they contributed to this module.
The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
USF Health requires CME faculty to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may/will discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
USF is an Equal Opportunity/ Equal Access/ Affirmative Action Institution.
If you have technical queries about using this site, please contact: firstname.lastname@example.org.
If you have credit related queries, please contact: email@example.comPractice Hepatology current certification period
This activity is intended for physicians and other healthcare professionals involved in the management of patients with viral hepatitis.Goal:
The goal of this activity is to provide a comprehensive clinical reference resource on the prevention, diagnosis, and treatment of viral hepatitis.Learning Objectives:
At the conclusion of this activity, participants should be able to:
This program is supported by educational grants from AbbVie and Gilead Sciences.
This activity is intended for physicians and other healthcare professionals involved in the management of patients with HIV.Goal:
The goal of this activity is to provide a comprehensive clinical reference resource on the prevention, diagnosis, and treatment of HIV disease.Learning Objectives:
At the conclusion of this activity, participants should be able to:
This program is supported by educational grants from Gilead Sciences, Janssen Therapeutics, and ViiV.
inPractice offers physicians AMA PRA Category 1 CreditTM for participation in this individual Internet point-of-care activity. Physicians may claim 0.5 credits per search. To claim point-of-care (PoC) CME credit through inPractice, eligible physicians must complete the following steps:
After submitting the evaluation, you will be presented with your online CME certificate as a pdf file. Records of all CME activities completed can be found on the "My CME" page.